Suchergebnisse - "Janjigian, Yelena Y"

PubPharm (8)

1

Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer

enthalten in: Thoracic surgery clinics | 2022

von Yang, J. | Janjigian, Y.

2

MATTERHORN : phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

enthalten in: Future oncology (London, England) | 2022

von Janjigian, Y. | Van Cutsem, E. | Muro, K. | +9

3

Checkpoint blockade in esophagogastric cancer

enthalten in: Journal of surgical oncology | 2018

von Cohen, N. | Strong, V. | Janjigian, Y.

4

89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2017

von Price, E. | Carnazza, K. | Carlin, S. | +7

5

Clinical impact of tumour biology in the management of gastroesophageal cancer

enthalten in: Nature reviews. Clinical oncology | 2016

von Lordick, F. | Janjigian, Y.

6

HER2 amplification : a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

enthalten in: Cancer discovery | 2012

von Takezawa, K. | Pirazzoli, V. | Arcila, M. | +13

7

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2011

von Janjigian, Y. | Azzoli, C. | Krug, L. | +8

8

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer

enthalten in: Journal of neuro-oncology | 2010

von De Braganca, K. | Janjigian, Y. | Azzoli, C. | +6

1
[1]